Search

everythinglearnresearchcommunity

for

Search:↓

The user shared progress pictures after four months of using finasteride, minoxidil, a dermaroller, and biotin for hair loss. They discussed their treatment regimen and results.

A user's 3-month progress with a combination of finasteride, minoxidil and dermarolling for hair loss; other users shared their experiences and advice.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

A user's progress with treating their hair loss, including using finasteride, minoxidil, retinoic acid, dermapenning twice weekly and ket 2% shampoo two to three times per week. Other users offered advice such as not derma penning too often or shaving the area bald for a couple of months.

The user shared progress after two months of using finasteride, serioxyl, and NOOANCE casque Pro for alopecia. They are documenting their hair loss treatment journey.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The user is one month into their FUE treatment and has just undergone PRP treatment at American Mane in Miami. They plan to start using minoxidil and LLT, take xpecia with saw palmetto, and try Exosome from ExoScrt and PRP for better hair growth results.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

User shares 1-month vs 9-month finasteride results for hair loss. Commenters discuss photo angles, hair regrowth, and side effects.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The positive effects of one year of treatments with topical minoxidil and oral finasteride for hair loss, with encouraging progress pictures as evidence.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.

A user shared their one-month progress using Minoxidil and RU58841 for hair loss, noting significant shedding after micro-needling and seeking opinions on their regrowth. They stopped micro-needling and added RU58841 to their treatment.

User shared progress pictures after one month of using finasteride, dutasteride, minoxidil, RU58841, dermarolling, and vitamins for hair loss. They reported positive results.

The user shared progress pictures after 2 months of using Minoxidil 5%, Forcapil, and dermarolling 1.5mm. They experienced initial shedding but noticed slow hair regrowth.

Hair loss treatments and the user's plan to start using Pyrilutamide, a combination of Minoxidil and Finasteride.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The conversation is about a user's 3-month hair regrowth progress using finasteride, minoxidil, and a 0.5mm dermaroller, with recent addition of caffeine shampoo. Users are responding positively and inquiring about application methods.